1887

Abstract

is a recently emerged multidrug-resistant fungal pathogen that causes life-threatening infections to the human population worldwide. Recent rampant outbreaks of in coronavirus disease 2019 (COVID-19) patients, together with outbreaks in over 45 countries, highlight its threat to patients and healthcare economies. Unlike other pathogenic species, is capable of surviving in abiotic surfaces of healthcare facilities for prolonged periods, leading to increased risk of transmission within nosocomial settings. is resistant to multiple classes of antifungal agents, forms dry biofilms and transmits independently to regional epicentres, making its eradication from nosocomial environment arduous. The lack of strategies for environmental decontamination of from nosocomial settings is evident from the generic guidance and recommendations provided by leading global healthcare bodies. Therefore, this minireview discusses the current guidelines for environmental decontamination of and compounds and strategies currently under investigation for potential future use. While established guidelines recommend the use of products mainly consisting of sodium hypochlorite and hydrogen peroxide, initial works have been reported on the promising anti- properties of various other compounds and some biocompatible alternatives. Further validation of these approaches, coupled up with environmentally friendly decontamination protocols, are warranted to achieve superior elimination of from healthcare settings.

  • This is an open-access article distributed under the terms of the Creative Commons Attribution NonCommercial License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001548
2022-06-10
2022-06-25
Loading full text...

Full text loading...

/deliver/fulltext/jmm/71/6/jmm001548.html?itemId=/content/journal/jmm/10.1099/jmm.0.001548&mimeType=html&fmt=ahah

References

  1. Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K et al. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol 2009; 53:41–44 [View Article] [PubMed]
    [Google Scholar]
  2. Du H, Bing J, Hu T, Ennis CL, Nobile CJ et al. Candida auris: Epidemiology, biology, antifungal resistance, and virulence. PLoS Pathog 2020; 16:e1008921 [View Article] [PubMed]
    [Google Scholar]
  3. CDC Tracking Candida auris Atlanta, GA: Centers for Disease Control and Prevention; 2021 https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html
  4. Chowdhary A, Voss A, Meis JF. Multidrug-resistant Candida auris: “new kid on the block” in hospital-associated infections?. J Hosp Infect 2016; 94:209–212 [View Article] [PubMed]
    [Google Scholar]
  5. Rudramurthy SM, Chakrabarti A, Paul RA, Sood P, Kaur H et al. Candida auris candidaemia in Indian ICUs: analysis of risk factors. J Antimicrob Chemother 2017; 72:1794–1801 [View Article] [PubMed]
    [Google Scholar]
  6. Jeffery-Smith A, Taori SK, Schelenz S, Jeffery K, Johnson EM et al. Candida auris: a review of the literature. Clin Microbiol Rev 2018; 31:e00029-17 [View Article] [PubMed]
    [Google Scholar]
  7. Hata DJ, Humphries R, Lockhart SR. for the College of American Pathologists Microbiology Committee Candida auris: an emerging yeast pathogen posing distinct challenges for laboratory diagnostics, treatment, and infection prevention. Arch Pathol Lab Med 2019; 144:107–114 [View Article] [PubMed]
    [Google Scholar]
  8. Ademe M, Girma F. Candida auris: from multidrug resistance to pan-resistant strains. Infect Drug Resist 2020; 13:1287–1294 [View Article] [PubMed]
    [Google Scholar]
  9. PHE Candida auris identified in England United Kingdom: Public Health England; 2017 https://www.gov.uk/government/publications/candida-auris-emergence-in-england/candida-auris-identified-in-england
  10. ECDC Candida auris in healthcare settings –Europe Stockholm: European Centre for Disease Prevention and Control; 2016 https://www.ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/Candida-in-healthcare-settings_19-Dec-2016.pdf
  11. CDC Candida auris clinical update Atlanta, GA: Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Foodborne, Waterborne, and Environmental Diseases (DFWED); 2017 https://www.cdc.gov/fungal/candida-auris/c-auris-alert-09-17.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Ffungal%2Fdiseases%2Fcandidiasis%2Fc-auris-alert-09-17.html
  12. Cortegiani A, Misseri G, Fasciana T, Giammanco A, Giarratano A et al. Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris. J Intensive Care 2018; 6:69 [View Article] [PubMed]
    [Google Scholar]
  13. Prestel C, Anderson E, Forsberg K, Lyman M, de Perio MA et al. Candida auris Outbreak in a COVID-19 Specialty Care Unit - Florida, July-August 2020. MMWR Morb Mortal Wkly Rep 2021; 70:56–57 [View Article] [PubMed]
    [Google Scholar]
  14. Rodriguez JY, Le Pape P, Lopez O, Esquea K, Labiosa AL et al. Candida auris: a latent threat to critically Ill patients with coronavirus disease 2019. Clin Infect Dis 2021; 73:e2836–e2837 [View Article] [PubMed]
    [Google Scholar]
  15. Magnasco L, Mikulska M, Giacobbe DR, Taramasso L, Vena A et al. Spread of carbapenem-resistant gram-negatives and Candida auris during the COVID-19 pandemic in critically Ill patients: one step back in antimicrobial stewardship?. Microorganisms 2021; 9:1–10 [View Article] [PubMed]
    [Google Scholar]
  16. Villanueva-Lozano H, Treviño-Rangel R de J, González GM, Ramírez-Elizondo MT, Lara-Medrano R et al. Outbreak of Candida auris infection in a COVID-19 hospital in Mexico. Clin Microbiol Infect 2021; 8:813–816 [View Article] [PubMed]
    [Google Scholar]
  17. Ku TSN, Walraven CJ, Lee SA. Candida auris: Disinfectants and Implications for Infection Control. Front Microbiol 2018; 9:726 [View Article] [PubMed]
    [Google Scholar]
  18. Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis 2017; 64:134–140 [View Article] [PubMed]
    [Google Scholar]
  19. Chowdhary A, Anil Kumar V, Sharma C, Prakash A, Agarwal K et al. Multidrug-resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis 2014; 33:919–926 [View Article] [PubMed]
    [Google Scholar]
  20. Calvo B, Melo ASA, Perozo-Mena A, Hernandez M, Francisco EC et al. First report of Candida auris in America: Clinical and microbiological aspects of 18 episodes of candidemia. J Infect 2016; 73:369–374 [View Article] [PubMed]
    [Google Scholar]
  21. Casadevall A, Kontoyiannis DP, Robert V. On the emergence of Candida auris: climate change, azoles, swamps, and birds. mBio 2019; 10:e01397-19 [View Article] [PubMed]
    [Google Scholar]
  22. Chow NA, Gade L, Tsay SV, Forsberg K, Greenko JA et al. Multiple introductions and subsequent transmission of multidrug-resistant Candida auris in the USA: a molecular epidemiological survey. Lancet Infect Dis 2018; 18:1377–1384 [View Article] [PubMed]
    [Google Scholar]
  23. Welsh RM, Bentz ML, Shams A, Houston H, Lyons A et al. Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic health care surface. J Clin Microbiol 2017; 55:2996–3005 [View Article] [PubMed]
    [Google Scholar]
  24. Piedrahita CT, Cadnum JL, Jencson AL, Shaikh AA, Ghannoum MA et al. Environmental surfaces in healthcare facilities are a potential source for transmission of Candida auris and other candida species. Infect Control Hosp Epidemiol 2017; 38:1107–1109 [View Article] [PubMed]
    [Google Scholar]
  25. Biswal M, Rudramurthy SM, Jain N, Shamanth AS, Sharma D et al. Controlling a possible outbreak of Candida auris infection: lessons learnt from multiple interventions. J Hosp Infect 2017; 97:363–370 [View Article] [PubMed]
    [Google Scholar]
  26. Kenters N, Kiernan M, Chowdhary A, Denning DW, Pemán J et al. Control of Candida auris in healthcare institutions: Outcome of an International Society for Antimicrobial Chemotherapy expert meeting. Int J Antimicrob Agents 2019; 54:400–406 [View Article] [PubMed]
    [Google Scholar]
  27. Chaabane F, Graf A, Jequier L, Coste AT. Review on antifungal resistance mechanisms in the emerging pathogen Candida auris. Front Microbiol 2019; 10:1–8 [View Article] [PubMed]
    [Google Scholar]
  28. EPA List P: Antimicrobial products registered with EPA for claims against Candida auris Washington, DC: United States Environmental Protection Agency; 2021 https://www.epa.gov/pesticide-registration/list-p-antimicrobial-products-registered-epa-claims-against-candida-auris
  29. EPA List K: EPA’s registered antimicrobial products effective against Clostridium difficile spores Washington, DC: United States Environmental Protection Agency; 2021 https://www.epa.gov/pesticide-registration/list-k-epas-registered-antimicrobial-products-effective-against-clostridium
  30. PHE Guidance for the Laboratory Investigation, Management and Infection Prevention and Control for Cases of Candida auris, 2nd ed. London, UK: Public Health England; 2017 pp 1–16
    [Google Scholar]
  31. ECDC Candida auris in healthcare settings –Europe Stockholm: European Centre for Disease Prevention and Control; 2016 https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/Candida-in-healthcare-settings_19-Dec-2016.pdf
  32. PAHO/WHO Epidemiological alert: Candida auris outbreaks in health care services Washington, D.C.: Pan American Health Organization / World Health Organization; 2016 https://www.paho.org/hq/dmdocuments/2016/2016-oct-3-phe-candida-auris-epi-alert.pdf
  33. Queensland-Health Infection prevention and control of Candida auris Brisbane, Australia: State of Queensland (Queensland Health); 2019 https://www.health.qld.gov.au/__data/assets/pdf_file/0028/722827/Candida-auris-guideline.pdf
  34. PIDAC Interim guide for infection prevention and control of Candida auris Ontario, Canada: Provincial Infectious Diseases Advisory Committe, Public Health Ontario; 2019 https://www.publichealthontario.ca/-/media/documents/p/2019/pidac-ipac-candida-auris.pdf?sc_lang=en
  35. Abdolrasouli A, Armstrong-James D, Ryan L, Schelenz S. In vitro efficacy of disinfectants utilised for skin decolonisation and environmental decontamination during a hospital outbreak with Candida auris. Mycoses 2017; 60:758–763 [View Article] [PubMed]
    [Google Scholar]
  36. Cadnum JL, Shaikh AA, Piedrahita CT, Sankar T, Jencson AL et al. Effectiveness of disinfectants against Candida auris and other candida species. Infect Control Hosp Epidemiol 2017; 38:1240–1243 [View Article] [PubMed]
    [Google Scholar]
  37. Fu L, Le T, Liu Z, Wang L, Guo H et al. Different efficacies of common disinfection methods against Candida auris and other candida species. J Infect Public Health 2020; 13:730–736 [View Article] [PubMed]
    [Google Scholar]
  38. Kean R, McKloud E, Townsend EM, Sherry L, Delaney C et al. The comparative efficacy of antiseptics against Candida auris biofilms. Int J Antimicrob Agents 2018; 52:673–677 [View Article] [PubMed]
    [Google Scholar]
  39. Kean R, Sherry L, Townsend E, McKloud E, Short B et al. Surface disinfection challenges for Candida auris: an in-vitro study. J Hosp Infect 2018; 98:433–436 [View Article] [PubMed]
    [Google Scholar]
  40. Kumar JA, Cadnum JL, Jencson AL, Donskey CJ. Efficacy of a multi-purpose high level disinfection cabinet against Candida auris and other health care-associated pathogen. Am J Infect Control 2020; 48:849–850 [View Article] [PubMed]
    [Google Scholar]
  41. Kumar JA, Cadnum JL, Jencson AL, Donskey CJ. Are reduced concentrations of chlorine-based disinfectants effective against Candida auris?. Am J Infect Control 2020; 48:448–450 [View Article] [PubMed]
    [Google Scholar]
  42. Ledwoch K, Maillard JY. Candida auris dry surface biofilm (DSB) for disinfectant efficacy testing. Materials (Basel) 2018; 12:1–10 [View Article] [PubMed]
    [Google Scholar]
  43. Livingston S, Cadnum JL, Gestrich S, Jencson AL, Donskey CJ. Efficacy of automated disinfection with ozonated water in reducing sink drainage system colonization with Pseudomonas species and Candida auris. Infect Control Hosp Epidemiol 2018; 39:1497–1498 [View Article] [PubMed]
    [Google Scholar]
  44. Müller P, Tan CK, Ißleib U, Paßvogel L, Eilts B et al. Investigation of the susceptibility of Candida auris and Candida albicans to chemical disinfectants using European Standards EN 13624 and EN 16615. J Hosp Infect 2020; 105:648–656 [View Article] [PubMed]
    [Google Scholar]
  45. Rutala WA, Gergen MF, Sickbert-Bennett EE, Anderson DJ, Weber DJ et al. Antimicrobial activity of a continuously active disinfectant against healthcare pathogens. Infect Control Hosp Epidemiol 2019; 40:1284–1286 [View Article] [PubMed]
    [Google Scholar]
  46. Rutala WA, Kanamori H, Gergen MF, Sickbert-Bennett EE, Weber DJ. Susceptibility of Candida auris and Candida albicans to 21 germicides used in healthcare facilities. Infect Control Hosp Epidemiol 2019; 40:380–382 [View Article] [PubMed]
    [Google Scholar]
  47. Stoffel JJ, Kohler Riedi PL, Hadj Romdhane B. A multimodel regime for evaluating effectiveness of antimicrobial wound care products in microbial biofilms. Wound Repair Regen 2020; 28:438–447 [View Article]
    [Google Scholar]
  48. Vargas-Cruz N, Reitzel RA, Rosenblatt J, Chaftari A-M, Wilson Dib R et al. Nitroglycerin-Citrate-Ethanol Catheter Lock Solution Is Highly Effective for In Vitro Eradication of Candida auris Biofilm. Antimicrob Agents Chemother 2019; 63:e00299-19 [View Article] [PubMed]
    [Google Scholar]
  49. Sexton DJ, Welsh RM, Bentz ML, Forsberg K, Jackson B et al. Evaluation of nine surface disinfectants against Candida auris using a quantitative disk carrier method: EPA SOP-MB-35. Infect Control Hosp Epidemiol 2020; 41:1219–1221 [View Article] [PubMed]
    [Google Scholar]
  50. Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A et al. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control 2016; 5:1–7 [View Article] [PubMed]
    [Google Scholar]
  51. Truong LN, Whitlock BD. Efficacy of compressed sodium chloride (CSC) against E. coli and Candida auris in minutes and methods improvement for testing. Sci Rep 2021; 11:1–6 [View Article] [PubMed]
    [Google Scholar]
  52. Whitlock BD, Smith SW. Compressed sodium chloride as a fast-acting antimicrobial surface: results of a pilot study. J Hosp Infect 2016; 94:182–184 [View Article] [PubMed]
    [Google Scholar]
  53. Quan FS, Rubino I, Lee SH, Koch B, Choi HJ. Universal and reusable virus deactivation system for respiratory protection. Sci Rep 2017; 7:1–10 [View Article] [PubMed]
    [Google Scholar]
  54. Kanamori H, Weber DJ, Rutala WA. Healthcare outbreaks associated with a water reservoir and infection prevention strategies. Clin Infect Dis 2016; 62:1423–1435 [View Article] [PubMed]
    [Google Scholar]
  55. Kizny Gordon AE, Mathers AJ, Cheong EYL, Gottlieb T, Kotay S et al. The hospital water environment as a reservoir for carbapenem-resistant organisms causing hospital-acquired infections-a systematic review of the literature. Clin Infect Dis 2017; 64:1435–1444 [View Article] [PubMed]
    [Google Scholar]
  56. Bialoszewski D, Pietruczuk-Padzik A, Kalicinska A, Bocian E, Czajkowska M et al. Activity of ozonated water and ozone against Staphylococcus aureus and Pseudomonas aeruginosa biofilms. Med Sci Monit 2011; 17:BR339–344 [View Article] [PubMed]
    [Google Scholar]
  57. César J, Sumita TC, Junqueira JC, Jorge AOC, do Rego MA. Antimicrobial effects of ozonated water on the sanitization of dental instruments contaminated with E. coli, S. aureus, C. albicans, or the spores of B. atrophaeus. J Infect Public Health 2012; 5:269–274 [View Article]
    [Google Scholar]
  58. Hübner NO, Siebert J, Kramer A. Octenidine dihydrochloride, a modern antiseptic for skin, mucous membranes and wounds. Skin Pharmacol Physiol 2010; 23:244–258 [View Article] [PubMed]
    [Google Scholar]
  59. Koburger T, Hübner NO, Braun M, Siebert J, Kramer A. Standardized comparison of antiseptic efficacy of triclosan, PVP-iodine, octenidine dihydrochloride, polyhexanide and chlorhexidine digluconate. J Antimicrob Chemother 2010; 65:1712–1719 [View Article] [PubMed]
    [Google Scholar]
  60. Bruls WA, Slaper H, van der Leun JC, Berrens L. Transmission of human epidermis and stratum corneum as a function of thickness in the ultraviolet and visible wavelengths. Photochem Photobiol 1984; 40:485–494 [View Article] [PubMed]
    [Google Scholar]
  61. Nerandzic MM, Cadnum JL, Pultz MJ, Donskey CJ. Evaluation of an automated ultraviolet radiation device for decontamination of Clostridium difficile and other healthcare-associated pathogens in hospital rooms. BMC Infect Dis 2010; 10:1–8 [View Article] [PubMed]
    [Google Scholar]
  62. Cadnum JL, Tomas ME, Sankar T, Jencson A, Mathew JI et al. Effect of variation in test methods on performance of ultraviolet-C radiation room decontamination. Infect Control Hosp Epidemiol 2016; 37:555–560 [View Article] [PubMed]
    [Google Scholar]
  63. Risović D, Maver-Bišćanin M, Mravak-Stipetić M, Bukovski S, Bišćanin A. Quantitative investigation of efficiency of ultraviolet and visible light in eradication of Candida albicans in vitro. Photomed Laser Surg 2014; 32:232–239 [View Article] [PubMed]
    [Google Scholar]
  64. Cadnum JL, Shaikh AA, Piedrahita CT, Jencson AL, Larkin EL et al. Relative resistance of the emerging fungal pathogen Candida auris and other candida species to killing by ultraviolet light. Infect Control Hosp Epidemiol 2018; 39:94–96 [View Article] [PubMed]
    [Google Scholar]
  65. de Groot T, Chowdhary A, Meis JF, Voss A. Killing of Candida auris by UV-C: Importance of exposure time and distance. Mycoses 2019; 62:408–412 [View Article] [PubMed]
    [Google Scholar]
  66. Ponnachan P, Vinod V, Pullanhi U, Varma P, Singh S et al. Antifungal activity of octenidine dihydrochloride and ultraviolet-C light against multidrug-resistant Candida auris. J Hosp Infect 2019; 102:120–124 [View Article] [PubMed]
    [Google Scholar]
  67. Lemons AR, McClelland TL, Martin SB, Lindsley WG, Green BJ. Inactivation of the multi-drug resistant pathogen Candida auris using ultraviolet germicidal irradiation (UVGI). J Hosp Infect 2020; S0195-6701:30186–30189
    [Google Scholar]
  68. Maslo C, du Plooy M, Coetzee J. The efficacy of pulsed-xenon ultraviolet light technology on Candida auris. BMC Infect Dis 2019; 19:1–3 [View Article] [PubMed]
    [Google Scholar]
  69. Astrid F, Beata Z, Julia E, Elisabeth P et al. The use of a UV-C disinfection robot in the routine cleaning process: a field study in an Academic hospital. Antimicrob Resist Infect Control 2021; 10:84 [View Article] [PubMed]
    [Google Scholar]
  70. Wainwright M, Maisch T, Nonell S, Plaetzer K, Almeida A et al. Photoantimicrobials-are we afraid of the light?. Lancet Infect Dis 2017; 17:e49–e55 [View Article] [PubMed]
    [Google Scholar]
  71. Dai T, Fuchs BB, Coleman JJ, Prates RA, Astrakas C et al. Concepts and principles of photodynamic therapy as an alternative antifungal discovery platform. Front Microbiol 2012; 3:1–16 [View Article] [PubMed]
    [Google Scholar]
  72. Pereira Gonzales F, Maisch T. Photodynamic inactivation for controlling Candida albicans infections. Fungal Biol 2012; 116:1–10 [View Article] [PubMed]
    [Google Scholar]
  73. Tan J, Liu Z, Sun Y, Yang L, Gao L. Inhibitory effects of photodynamic inactivation on planktonic cells and biofilms of Candida auris. Mycopathologia 2019; 184:525–531 [View Article] [PubMed]
    [Google Scholar]
  74. Arastehfar A, Shaban T, Zarrinfar H, Roudbary M, Ghazanfari M et al. Candidemia among Iranian patients with severe COVID-19 admitted to ICUs. J Fungi (Basel) 2021; 7:280 [View Article] [PubMed]
    [Google Scholar]
  75. Rajni E, Singh A, Tarai B, Jain K, Shankar R et al. A high frequency of Candida auris blood stream infections in coronavirus disease 2019 patients admitted to intensive care units, northwestern india: a case control study. Open Forum Infect Dis 2021; 8:ofab452 [View Article] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001548
Loading
/content/journal/jmm/10.1099/jmm.0.001548
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error